Synexa Life Sciences acquires Alderley Analytical, expanding bioanalytical capabilities
TThe acquisition of Alderley Analytical by Synexa Life Sciences marks a significant development in the bioanalytical services sector. This strategic move, announced on 7 October 2024, aims to broaden Synexa’s capabilities in biomarker and bioanalytical assays, particularly in the areas of mass spectrometry and ligand binding assays.
Synexa Life Sciences, headquartered in Leiden, The Netherlands, has established itself as a specialist in biomarker and bioanalysis services. The company’s existing portfolio encompasses a wide range of complex and custom-designed assays, including biomarker identification and development, clinical bioanalysis, and soluble biomarker analysis. Their expertise extends to cell biology techniques such as flow cytometry and ELISpot, as well as genomic services supporting clinical trials and translational studies.
Alderley Analytical, based near Manchester, UK, brings to the table a comprehensive suite of bioanalytical services. Their specialisation in mass spectrometry and ligand binding assays complements Synexa’s existing capabilities. Alderley’s services span the drug development continuum, from discovery through preclinical to clinical stages, covering small molecules, large molecules, peptides, oligonucleotides, and biomarkers.
Enhanced service offerings
The integration of Alderley Analytical into Synexa Life Sciences is expected to yield a more comprehensive range of services for an expanded customer base. This merger particularly strengthens the group’s position in both large and small molecule drug development, ranging from preclinical work to phase III clinical studies.
Emile Lens, CEO of Synexa Life Sciences, emphasised the strategic importance of this acquisition, saying: “Welcoming Alderley Analytical to our group is a pivotal step in Synexa’s growth strategy, enhancing our capabilities in bioanalytical services and broadening our geographic reach as a leading European specialist biomarker and bioanalysis services company.”
Geographical expansion
This acquisition not only enhances Synexa’s technical capabilities but also expands its geographical footprint in Europe. Alderley Analytical’s recently established state-of-the-art GLP/GCP-accredited laboratory near Manchester provides Synexa with a strong presence in the UK, complementing its existing operations. Paul Holme, CEO and Co-Founder of Alderley Analytical, expressed enthusiasm about the merger, noting: “We are thrilled to join forces with Synexa Life Sciences. This step represents a significant opportunity to enhance our teams’ bioanalytical services and broaden our impact on drug development.”
Industry implications
The merger of these two companies reflects a broader trend in the life sciences industry towards consolidation and expansion of service offerings. By combining complementary expertise and technologies, companies like Synexa aim to provide more comprehensive solutions to their clients.
This acquisition is particularly noteworthy in the context of biomarker analysis, an increasingly critical component of drug development and personalised medicine. The combined capabilities of Synexa and Alderley Analytical in this area could contribute to more efficient and targeted drug development processes, potentially benefiting both pharmaceutical companies and patients.
As part of Synexa’s ‘buy and build’ growth strategy, this acquisition represents a significant step towards the company’s vision of becoming ‘the scientific partner of choice for biomarker and bioanalytical solutions’.
The integration of Alderley Analytical’s expertise and facilities with Synexa’s existing capabilities is likely to enhance the combined entity’s competitive position in the European bioanalytical services market.
Emile Lens, CEO of Synexa Life Sciences